The FDA has extended the emergency use authorisation for Gilead Sciences' antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug.
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, acc
Biogen's difficult launch of controversial Alzheimer's therapy Aduhelm has been made even harder by a proposal by Medicare to cover the drug only for certain patients enrolled in clinical t
Regeneron has enlisted the aid of Ultragenyx to add momentum to the rollout of its recently-approved Evkeeza outside the US, which was approved for an inherited form of elevated cholesterol
The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead.
Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling multiple sclerosis drug Gilenya in the US for almost six years.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.